The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

The cell and gene therapy contract development and manufacturing organization (CDMO) market has witnessed exponential growth in recent years. This surge is driven by various factors, and its trajectory shows no signs of slowing down. Let’s explore the dynamics fueling this market.

Market Growth Overview

• 2023 Growth Stats: The market grew from $4.24 billion in 2023 to $5.41 billion in 2024, reflecting a compound annual growth rate (CAGR) of 27.7%.
• Projected Growth: By 2028, the market is expected to reach $14.52 billion, with a CAGR of 28.0%.

Key Drivers of Historic Growth

• Technological Advancements: Rapid improvements in technology have accelerated the development and manufacturing processes.
• Favorable Regulatory Frameworks: Governments and regulatory bodies have created environments conducive to innovation and growth.
• Increased Investment: Significant capital infusion has supported research, development, and scaling of production.
• High Prevalence of Genetic Disorders: The rise in genetic disorders has necessitated the development of targeted therapies.
• Strategic Partnerships: Collaborations between companies have enhanced capabilities and expanded market reach.

View More On The Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Future Growth Catalysts

• Expanded Therapeutic Applications: Broader applications for cell and gene therapies are driving demand.
• Regulatory Evolution: Ongoing regulatory changes are expected to further support innovation and market expansion.
• Increased Investment: Continued financial backing will propel research and development.
• Technological Innovations: New technologies will continue to improve efficiency and scalability.
• Global Collaboration: Partnerships across borders are fostering knowledge sharing and resource pooling.

Major Trends Shaping the Future

• Personalized Therapies: Growing demand for therapies tailored to individual patients.
• Automation and Digitalization: The rise of automated processes and digital tools to enhance production efficiency.
• Manufacturing Capacity Expansion: Companies are increasing their production capabilities to meet rising demand.
• Novel Delivery Systems: Development of new methods to deliver therapies more effectively.
• Sustainability Focus: Heightened emphasis on reducing the environmental impact of manufacturing processes.

Rising Cancer Rates Fuel Market Expansion

• Cancer Prevalence: The growing number of cancer cases globally is a significant driver of the CDMO market.
  • Factors include aging populations, lifestyle changes, environmental exposures, and improved detection.
• Role of CDMOs: These organizations are crucial in developing and manufacturing innovative treatments that target cancer more effectively.
  • Example: In the UK, cancer cases are projected to rise from 3 million in 2022 to 5.3 million by 2040, emphasizing the need for advanced therapies.

Innovations in Cell and Gene Therapy Manufacturing

• PluriMatrix Technology: Companies like Pluri are introducing advanced technologies to improve manufacturing processes.
  • Key Features: 3D cell expansion, high yield, consistent quality, automation, and control.
  • PluriCDMO: Launched in January 2024, this division offers end-to-end cell therapy manufacturing services, leveraging PluriMatrix technology.

Strategic Acquisitions and Expansions

• Ajinomoto’s Acquisition of Forge Biologics:
  • Details: In November 2023, Ajinomoto Co. Inc. acquired Forge Biologics for $620 million.
  • Impact: This acquisition strengthens Ajinomoto’s global capabilities in gene therapy manufacturing, particularly in adeno-associated virus (AAV) and plasmid gene therapy.

Regional Insights and Market Segmentation

• Leading Regions:
  • North America: The largest region in the market in 2023.
  • Asia-Pacific: Expected to be the fastest-growing region during the forecast period.
• Market Segmentation:
  • By Product Type: Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy.
  • By Phase: Phase 1, Phase 2, Phase 3, Phase 4.
  • By Indication: Oncology, Infectious Diseases, Neurological Disorders, Rare Diseases, Other Indications.

Conclusion
The cell and gene therapy CDMO market is on a trajectory of rapid growth, driven by technological advancements, increased investment, and the rising demand for personalized therapies. As the market continues to evolve, it will play a crucial role in addressing global health challenges, particularly in the fight against cancer. With continued innovation and strategic expansions, the future looks promising for this dynamic and transformative industry.

Request A Sample Of The Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15753&type=smp